+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genentech, Inc. - logo

Genentech, Inc., a biotechnology company, engages in the research, development, manufacture, and marketing of biotechnology products for treating patients with serious or life-threatening diseases in the United States. It offers molecular entities and medicines in the areas of oncology, immunology, neuroscience, metabolism, and infectious diseases. The company was founded in 1976 and is headquartered in South San Francisco, California. Genentech operates as a subsidiary of Roche Holdings, Inc.

Company Snapshots: US Pharmaceuticals - Product Thumbnail Image

Company Snapshots: US Pharmaceuticals

  • Newsletter
  • May 2025
  • 35 Pages
  • United States
From
Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028

  • Report
  • March 2020
  • 154 Pages
  • Global
From
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 74 Pages
  • Global
From
Industry Snapshots: US Pharmaceuticals - Product Thumbnail Image

Industry Snapshots: US Pharmaceuticals

  • Newsletter
  • May 2025
  • 50 Pages
  • United States
From
Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 555 Pages
  • Global
From
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drugs in Development, 2021 - Product Thumbnail Image

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drugs in Development, 2021

  • Report
  • November 2021
  • 126 Pages
  • Global
From
Ovarian Cancer: Opportunity Analysis and Forecasts to 2028 - Product Thumbnail Image

Ovarian Cancer: Opportunity Analysis and Forecasts to 2028

  • Report
  • September 2019
  • 162 Pages
  • Global
From
Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027 - Product Thumbnail Image

Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

  • Report
  • March 2019
  • 164 Pages
  • Global
From
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase - Product Thumbnail Image

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase

  • Drug Pipelines
  • October 2018
  • 98 Pages
  • Global
From
Pharmaceutical Manufacturing in California - Industry Market Research Report - Product Thumbnail Image

Pharmaceutical Manufacturing in California - Industry Market Research Report

  • Report
  • February 2020
  • 26 Pages
  • United States
From
Genentech USA Inc - Strategic SWOT Analysis Review - Product Thumbnail Image

Genentech USA Inc - Strategic SWOT Analysis Review

  • SWOT Analysis
  • January 2025
  • 36 Pages
  • United States
From
Genentech, Inc. - Company Profile and SWOT Analysis - Product Thumbnail Image

Genentech, Inc. - Company Profile and SWOT Analysis

  • SWOT Analysis
  • December 2024
  • 62 Pages
From
Loading Indicator